384 patients treated with Saxenda®and 2 (0.1%) of the 1,941 treated with placebo reported suicidal ideation; one of the Saxenda®treated patients attempted suicide. In a pediatric trial, 1(0.8%) of the 125
View tips for discussing weight management with parents or caregivers of adolescents with obesity. Read Important Safety and Prescribing Info, including Boxed Warning.
Pharmacologic Agents Chapter for Abdominal Obesity Liraglutide Liraglutide is a medication that has been approved to treat type 2 diabetes for several years, and received an indication for the treatment of obesity with a higher 3 mg dose under the trade name Saxenda in 2014. It belongs to the ...
Indicated for use in pediatric patients ≥12 years of age with a body weight >60 kg and an initial BMI corresponding to 30 kg/m2 for adults (obese) by international cut-offs.Various preparations of liraglutide are available; Saxenda injection is specifically FDA-labeled for use in chronic ...
1. Introduction Liraglutide (Saxenda, Victoza) is a glucagon-like-peptide-1 (GLP-1) analog that acts like incretin to increase insulin secretion through specific beta-cell receptors. Liraglutide shares a 97% homology with human GLP-1 and is approved for glycemic control in adults with type 2 ...